Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).

被引：9

作者：

Bendell, Johanna C.

Murphy, Janet E.

Mahalingam, Devalingam

Halmos, Balazs

Sirard, Cynthia A.

Landau, Steven B.

Ryan, David P.

机构：

[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA

[4] Columbia Univ, Med Ctr, New York, NY USA

[5] HeathCare Pharmaceut Inc, Cambridge, MA USA

[6] Healthcare Ventures, Cambridge, MA USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

111

引用

页数：1